Biomarkers in medicine · 2026
Inflammatory burden index and prognostic outcomes in gastrointestinal cancer: a meta-analysis.
СтатьяМетаанализОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Jia-Run, Qin Rong, Zhang Xi, Hu Xin-Rui
Аннотация
BACKGROUND: The Inflammatory Burden Index (IBI) has been identified as a significant prognostic factor in various gastrointestinal (GI) malignancies. However, despite extensive research, its prognostic value remains inconsistent. To clarify this association, we conducted a systematic meta-analysis following rigorous methodological standards.
METHODS: A comprehensive literature search was performed across PubMed, Web of Science, Embase, Scopus, and Cochrane databases. Ultimately, nine studies were included, covering multiple gastrointestinal cancer subtypes.
RESULTS: Our analysis demonstrated that an elevated IBI was significantly associated with poorer overall survival (OS) (HR = 2.14, 95% CI: 1.38-3.31, p = 0.001), disease-free survival (DFS) (HR = 1.75, 95% CI: 1.35-2.26, p < 0.001), and recurrence-free survival (RFS) (HR = 2.15, 95% CI: 1.59-2.92, p < 0.001). Furthermore, IBI levels were significantly correlated with several key clinicopathological factors including age, tumor size, lymph node metastases, lymph-vascular invasion, and neoadjuvant chemotherapy.
CONCLUSION: This meta-analysis suggests that elevated IBI might be a robust predictor for poor survival in GI cancer patients and correlates closely with advanced disease features including larger tumor size, lymph node metastases, and lymph-vascular invasion. These findings underscore IBI as a clinically relevant prognostic biomarker for GI malignancies.
METHODS: A comprehensive literature search was performed across PubMed, Web of Science, Embase, Scopus, and Cochrane databases. Ultimately, nine studies were included, covering multiple gastrointestinal cancer subtypes.
RESULTS: Our analysis demonstrated that an elevated IBI was significantly associated with poorer overall survival (OS) (HR = 2.14, 95% CI: 1.38-3.31, p = 0.001), disease-free survival (DFS) (HR = 1.75, 95% CI: 1.35-2.26, p < 0.001), and recurrence-free survival (RFS) (HR = 2.15, 95% CI: 1.59-2.92, p < 0.001). Furthermore, IBI levels were significantly correlated with several key clinicopathological factors including age, tumor size, lymph node metastases, lymph-vascular invasion, and neoadjuvant chemotherapy.
CONCLUSION: This meta-analysis suggests that elevated IBI might be a robust predictor for poor survival in GI cancer patients and correlates closely with advanced disease features including larger tumor size, lymph node metastases, and lymph-vascular invasion. These findings underscore IBI as a clinically relevant prognostic biomarker for GI malignancies.